<h1>Biomedical and Pharma</h1> <p>Singapore's biomedical sciences (BMS) sector is a state-built pillar of advanced manufacturing, spanning biopharmaceutical production, medical technology, and the research infrastructure that feeds both. The sector is promoted by the <a href="/en/knowledge/article/sgkb.business-industry.doing-business">Singapore Economic Development Board</a> (EDB) and regulated for drug manufacturing by the Health Sciences Authority (HSA). As of 2024, biopharmaceutical and medical-technology activity contributed about 1.9% of Singapore's GDP — the GDP denominator is Singapore's whole economy — and produced more than S$32 billion worth of products for global markets; that product value is an industry-output measure, not domestic healthcare spending (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). Singapore hosts more than 60 BMS manufacturing plants, over 30 research and development centres, and more than 80 regional headquarters, including eight of the world's top 10 biopharmaceutical companies by the government's count as of May 2026; the dated scale and output anchors are tabulated in <a href="/en/knowledge/dataset/sgkb.data.biomedical-pharma-anchors">biomedical pharma anchors</a> (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>; <a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). The sector sits alongside <a href="/en/knowledge/article/sgkb.business-industry.electronics-and-semiconductors">electronics and semiconductors</a> as a high-value manufacturing cluster within Singapore's broader <a href="/en/knowledge/article/sgkb.economy-finance.economy-overview">open economy</a>.</p> <h2>Economic scale and manufacturing output</h2> <p>The biomedical sciences sector employs more than 26,000 people in Singapore as of 2024, nearly triple the headcount of two decades earlier, across manufacturing, R&amp;D, regional headquarters, and supporting functions such as quality assurance, regulatory affairs, and supply chain (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). Employment spans both science and engineering roles and commercial, digital, and operations positions anchored by multinationals such as GSK and ResMed.</p> <p>Within Singapore's manufacturing statistics, biomedical manufacturing is tracked as its own cluster, split into pharmaceuticals and medical technology. In April 2026, biomedical manufacturing accounted for 11.3% of total manufacturing output on an index basis (2025 = 100), with pharmaceuticals at 3.7% and medical technology at 7.6% (<a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html">EDB Monthly Manufacturing Performance</a>). The cluster is cyclical and product-specific: biomedical output fell 16.1% year-on-year in April 2026 on softer medical-device demand and lower biologics production, even as the rest of manufacturing grew strongly (<a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/monthly-manufacturing-performance.html">EDB Monthly Manufacturing Performance</a>). Conversely, the biomedical manufacturing cluster grew 45.9% year-on-year in the fourth quarter of 2025, driven by higher production of a key high-value active pharmaceutical ingredient (<a href="https://www.sgpc.gov.sg/api/file/getfile/ESS%202025_Press%20Release_embargoed%20untl%2010Feb26%20at%208am.pdf?path=%2Fsgpcmedia%2Fmedia_releases%2Fmti%2Fpress_release%2FP-20260210-1%2Fattachment%2FESS+2025+Press+Release+embargoed+untl+10Feb26+at+8am.pdf">MTI Economic Survey of Singapore 2025, accessed Aug 2026</a>). These swings illustrate that Singapore's BMS sector is an export engine tied to global drug pipelines and device demand, not a proxy for domestic <a href="/en/knowledge/article/sgkb.healthcare.healthcare-system-overview">healthcare delivery</a>.</p> <h2>How the sector was built</h2> <p>Singapore's biomedical push is a deliberate, whole-of-government industrial strategy rather than organic cluster growth. The government launched the Biomedical Sciences initiative in June 2000, selecting life sciences as a fourth manufacturing pillar and coordinating industrial development (led by EDB's Biomedical Sciences Group), strategic venture investment (through the Bio<em>One Capital fund), and public research funding (through what became A</em>STAR's Biomedical Research Council) (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). The vision was to span the full value chain — from basic research through manufacturing to healthcare delivery — rather than remain a low-cost pill-pressing location.</p> <p>Biopolis, opened in October 2003 at <a href="/en/knowledge/article/sgkb.geography-urban-planning.ura-and-master-plan">one-north</a>, was conceived as the research cornerstone: a dedicated biomedical R&amp;D campus bringing public institutes and private laboratories together to create knowledge-intensive jobs (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). In parallel, JTC Corporation developed Tuas Biomedical Park as the manufacturing counterpart. Foreign pharmaceutical firms had manufactured in Singapore since the 1970s, but the 2000 initiative accelerated movement up the value chain into biologics, active pharmaceutical ingredients, and regional headquarters functions. The model mirrors Singapore's broader development approach: land and infrastructure from JTC, research translation through A*STAR, investment facilitation through EDB, and internationally recognised regulatory standards through HSA.</p> <h2>Manufacturing at Tuas Biomedical Park</h2> <p>Tuas Biomedical Park (TBP) in western Singapore is the primary manufacturing estate for pharmaceuticals, biologics, and medical technology. JTC markets TBP as a plug-and-play biomedical hub with purpose-built infrastructure — power, water, sewer, gas, telecommunications, and shared utilities including steam, chilled water, and waste treatment — so companies can commission plants quickly (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>). The park comprises Tuas Biomedical Park I (about 183 hectares) and Tuas Biomedical Park II (about 188 hectares), located near the Tuas Checkpoint to Malaysia and the developing Tuas Port (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>).</p> <p>Major global biopharma manufacturers operate at TBP, including Pfizer, Novartis, GSK, Roche, and MSD among the companies cited in parliamentary replies (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). GSK's vaccine production site in Tuas, for example, produces two vaccines covering approximately 45% of diseases causing paediatric mortality globally, and GSK employs about 1,600 people across its Singapore pharmaceutical and vaccine operations (<a href="https://www.jtc.gov.sg/about-jtc/news-and-stories/feature-stories/getting-the-formula-right-in-growing-local-biomedical-sector">JTC, accessed Aug 2026</a>). Manufacturing activities range from active pharmaceutical ingredients and final dosage forms (including injectables) to biologics, medical devices, and newer capabilities such as cell processing.</p> <p>JTC has also developed supporting infrastructure such as JTC BioMed Hub within TBP to cluster biomedical suppliers and SMEs, and a Biopharma Industry Council comprising government agencies and pharmaceutical companies based largely at the park to promote manufacturing excellence. Recent anchor investments include AstraZeneca's US$1.5 billion end-to-end antibody drug conjugate (ADC) manufacturing facility in Tuas South — the company's first global ADC site incorporating drug substance and drug product on one campus, targeted for operational readiness by 2029 with more than 800 jobs and net-zero emissions from day one (<a href="https://www.mti.gov.sg/newsroom/speech-by-dpm-and-minister-for-trade-and-industry-gan-kim-yong-at-astrazeneca-s-antibody-drug-conjugate--adc--manufacturing-facility-groundbreaking-ceremony/">MTI, accessed Aug 2026</a>; <a href="https://www.edb.gov.sg/en/about-edb/media-releases-publications/astrazeneca-to-hire-over-800-employees-for-antibody-drug-conjugate-facility-in-singapore.html">EDB, accessed Aug 2026</a>).</p> <h2>Research, innovation, and talent</h2> <p>Singapore's biomedical research infrastructure is concentrated at one-north, where Biopolis houses A<em>STAR biomedical research institutes alongside corporate laboratories. A</em>STAR's biomedical entities include the Bioinformatics Institute, Bioprocessing Technology Institute, Genome Institute of Singapore, Institute of Molecular and Cell Biology, Singapore Immunology Network, and others focused on areas from infectious disease to food and biotechnology (<a href="https://www.a-star.edu.sg/">A*STAR, accessed Aug 2026</a>). Biopolis was designed to co-locate public research with industry — early tenants included the Novartis Institute for Tropical Diseases and Johns Hopkins Singapore, alongside A*STAR institutes moving in from 2003 (<a href="https://www.nas.gov.sg/archivesonline/data/pdfdoc/2003102904.htm">NAS, accessed Aug 2026</a>). EDB describes one-north more broadly as hosting over 400 companies, 15 research institutes, and six institutions of higher learning as of 2025 (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>).</p> <p>A*STAR anchors research translation — converting discoveries into applications through industry partnerships and national platforms such as the Nucleic Acid Therapeutics Initiative (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). EDB also runs overseas training programmes that place Singapore graduates in multinational manufacturing sites before they return to local plants. As of 2025, Singapore reported more than 53,000 researchers nationally, with around 45% of ITE, polytechnic, and university graduates coming from STEM-related courses (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>). The sector's next growth areas — biologics, cell and gene therapies, digital health, and precision medicine — are expected to demand clinical expertise combined with data and computing skills (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>).</p> <h2>Regulation and manufacturing standards</h2> <p>Drug manufacturing in Singapore is regulated by the Health Sciences Authority (HSA), which is distinct from the clinical <a href="/en/knowledge/article/sgkb.healthcare.healthcare-system-overview">healthcare system</a> overseen by the Ministry of Health (MOH); MOH's clinical healthcare role is separate from HSA's factory licensing role. HSA GMP licensing covers local manufacturers of therapeutic products and active ingredients, which must comply with the current Pharmaceutical Inspection Co-operation Scheme (PIC/S) Guide to Good Manufacturing Practice (GMP) — the international standard for consistent production and quality control (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/gmp-gdp/">HSA, accessed Aug 2026</a>). Local manufacturers must pass HSA pre-approval GMP audits before receiving a manufacturer's licence; routine and unannounced audits follow (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/apply/">HSA, accessed Aug 2026</a>). Each licensed site must appoint responsible persons for production and quality operations with relevant practical experience (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/overview/">HSA, accessed Aug 2026</a>).</p> <p>HSA's PIC/S membership gives Singapore-manufactured drugs credibility in global supply chains: overseas regulators accept GMP evidence from PIC/S member authorities when registering products. HSA encourages companies planning new Singapore manufacturing sites to engage its GMP unit early in the design process (<a href="https://www.hsa.gov.sg/active-ingredients/manufacturers/apply-licence">HSA, accessed Aug 2026</a>). This regulatory reputation is part of Singapore's investment pitch — alongside infrastructure, talent, and intellectual-property protection — for high-value biologics and ADC production rather than commodity generics alone.</p> <h2>Strategic trade-offs and critical questions</h2> <p>The sector has two different success tests. An industrial-policy reading measures export value, fixed-asset investment, trusted regulation, high-skill jobs, and the ability to attract the next complex manufacturing platform; a domestic-benefit reading asks how far those gains strengthen local firms, research careers, resilience of essential supplies, and access to resulting medicines or devices. EDB and MTI evidence establishes the first set of outputs, but it does not by itself answer the distributional or healthcare questions in the second set (<a href="https://www.edb.gov.sg/en/business-insights/insights/singapores-rise-as-a-biomedical-sciences-powerhouse-the-talent-driving-its-next-chapter.html">EDB, accessed Aug 2026</a>; <a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>).</p> <p>There is a related resilience-versus-efficiency trade-off. Concentrating plants, suppliers, research institutions, and multinational headquarters in an integrated cluster can shorten development and manufacturing links, while dependence on global company pipelines means that a site closure or product-cycle change can affect output even when Singapore's fundamentals remain strong (<a href="https://www.jtc.gov.sg/find-land/jtc-key-estates/tuas-biomedical-park">JTC, accessed Aug 2026</a>; <a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). HSA's GMP and licensing standards protect quality and supply-chain credibility, but compliance, land, talent, and operating costs are also part of the competitiveness equation (<a href="https://www.hsa.gov.sg/therapeutic-products/manufacturing-import-wholesale/licence-to-manufacturer-import-or-wholesale/gmp-gdp/">HSA, accessed Aug 2026</a>). These are evaluation questions rather than evidence of failure: claims about “resilience,” “local capability,” or “public value” should specify the indicator, time period, population, and denominator being used.</p> <h2>Investment outlook and sector challenges</h2> <p>EDB attracted S$4.4 billion in fixed-asset investments for the biomedical sciences sector in 2025, projected to create 1,775 jobs over five years (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). The government characterises the outlook as strong, citing anchor projects such as AstraZeneca's ADC plant as evidence that Singapore continues to win complex manufacturing capabilities (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>).</p> <p>The sector is not without friction. Parliamentary questions in May 2026 followed announcements of local biopharma plant closures, prompting the Ministry of Trade and Industry to distinguish company-specific commercial decisions from a weakening of Singapore's overall value proposition (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). Rising operating costs and improving regional workforce capabilities in competing jurisdictions add pressure. The government's response emphasises productivity, automation, artificial intelligence, and robotics adoption by existing manufacturers, alongside continued investment in fundamentals — research infrastructure, regulatory quality, and talent pipelines (<a href="https://www.mti.gov.sg/newsroom/written-reply-to-pq-on-assessing-biomedical-sectors-resilience-and-recalibrating-singapore-s-long-term-economic-strategy-and-retain-mnc-manufacturers/">MTI, accessed Aug 2026</a>). For Singapore, the biomedical sciences sector remains a bet that a city-state with no domestic market can sustain premium manufacturing by offering trusted regulation, integrated research-to-factory infrastructure, and skilled labour at the frontier of biologics and precision medicine.</p>